In immunotherapy, blocking CTLA-4 with specific antibodies (such as ipilimumab) can release the brake on T cells, thereby stimulating a stronger immune response against cancer cells. This approach has shown promising results in treating certain cancers, and ongoing research is exploring its efficacy in gynecological malignancies.
